View Document Preview and Link Open Document File Size: 1,08 MB Share Result on Facebook
City Acute / / Company AEs / AstraZeneca / Glaxosmithkline plc / / Currency pence / / Event Product Issues / FDA Phase / Product Recall / / IndustryTerm investigational product / treatment groups / mg groups / mg / placebo groups / hoc computer-based search / chemical structure / food / / MedicalCondition CV disease / abdominal pain / Unrelieved constipation / hypertension / chronic non-cancer pain / atherogenesis / OWD syndrome / opioid bowel dysfunction / chronic use / electrolyte disorders / stroke / nausea / chronic opioid antagonists / diabetes / MI Myocardial infarction / syncope / pain / vomiting / drug withdrawal syndrome / OWD OWD syndrome / unstable angina / myocardial infarction / morphine-induced miosis / heart failure / opioid-induced constipation / full syndrome / diarrhea / chronic opioid users / illness / withdrawal symptoms / constipation / myocardial ischemia / Mental Disorders / / MedicalTreatment pain management / / Organization European Union Committee for Medicinal Products for Human Use / Food and Drug Administration / Event Adjudication Committee / Cardiovascular Event Adjudication Committee / Anesthetic and Analgesic Drug Products Advisory Committee / Advisory Committee / / Position Investigator / General / / Product μ-opioid receptor antagonists precipitating opioid / naloxone / syndrome / polyethylene glycol / K8 / OIC / / ProvinceOrState Michigan / / SocialTag 
Briefing Document Drug substance Naloxegol Date